 DURHAM, N.C.--BUSINESS WIRE--Precision BioSciences Inc. Nasdaq: DTIL, a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, today announced encouraging progress on two strategies designed to optimize the durability of allogeneic CAR T therapy in patients with relapsedrefractory RR non-Hodgkin lymphoma NHL. The Company reported updated interim results from its Phase 12a study of PBCAR0191, the 